In today's evolving, dynamic clinical development environment, central laboratories must adapt to meet the growing demand for early biomarker evaluation before advancement into clinical trials. Bringing biomarkers or novel technologies, into clinical research is becoming increasingly complex and often calls for exploratory biomarker research and new technology evaluation outside the regulatory confines of clinical trials. At Q² Solutions, our dedicated, state-of-the-art Translational Science and Innovation Laboratory (TSAIL) is designed to address these challenges and provide the agility and breadth of translational science capabilities and expertise required to bridge the gap between preclinical and early clinical drug development and to introduce new biomarker-assays into clinical study. This approach ensures that the most effective biomarkers and associated technologies are being validated earlier on and deployed rapidly to accelerate the development of therapeutics.
TSAIL focuses on biomarker discovery activities, exploratory clinical sample testing and new technology evaluation. The scientific team includes experts in anatomic pathology, flow cytometry, genomics, bioinformatics, and immunoassays including cell-based assay.
The center of innovation with access to a broad spectrum of scientific disciplines and expertise
TSAIL’s custom-designed, multidisciplinary space melds industry-leading expertise with numerous cutting-edge technology platforms to support all aspects of biomarker development and delivery. TSAIL supports fit-for-purpose validation by enabling customers to access a broad range of services, including tailored biomarker assay development, bioinformatics, data analytics, digital innovations, and the capability to evaluate novel technologies.